Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )
Safety and Efficacy of Drug Coated Balloon Therapy for Coronary In-stent Restenosis in Patients With Coronary Heart Disease Under the Guidance of QFR (UNIQUE-DCB-II Study)
Sponsor: Nanjing First Hospital, Nanjing Medical University
Listed as NCT04119986, this NA trial focuses on Coronary Heart Disease and remains actively recruiting participants. Sponsored by Nanjing First Hospital, Nanjing Medical University, it has been updated 9 times since 2026, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Jun 2025 — Present [monthly]
Not Yet Recruiting NA
-
Sep 2024 — Jun 2025 [monthly]
Not Yet Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
Dec 2023 — Jul 2024 [monthly]
Not Yet Recruiting NA
-
May 2022 — Dec 2023 [monthly]
Not Yet Recruiting NA
▶ Show 4 earlier versions
-
Oct 2021 — May 2022 [monthly]
Not Yet Recruiting NA
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting NA
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
-
Nov 2019 — Apr 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing First Hospital, Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .